Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Therachon closes $60mm mezzanine financing

Executive Summary

Rare disease-focused Therachon AG raised $60mm in a mezzanine financing led by Novo Holdings, which was joined by other new backers Cowen Healthcare Investments, Pfizer Ventures, and Tekla Capital Management, and returning shareholders OrbiMed, Bpifrance, and Inserm Transfert Initiative. A representative from Novo and Cowen join the board. Therachon will use the funds for ongoing development of its pipeline including lead candidate Phase I TA46 for achondroplasia.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies